

Matthew S Davids

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9349961/publications.pdf>

Version: 2024-02-01

169
papers

9,346
citations

76326

40
h-index

40979

93
g-index

169
all docs

169
docs citations

169
times ranked

10212
citing authors

#	ARTICLE	IF	CITATIONS
1	Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2016, 374, 311-322.	27.0	1,532
2	Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 826-833.	1.6	596
3	Ipilimumab for Patients with Relapse after Allogeneic Transplantation. <i>New England Journal of Medicine</i> , 2016, 375, 143-153.	27.0	488
4	Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2018, 19, 65-75.	10.7	314
5	Small molecules, big impact: 20 years of targeted therapy in oncology. <i>Lancet</i> , The, 2020, 395, 1078-1088.	13.7	302
6	Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study. <i>Lancet Oncology</i> , The, 2017, 18, 230-240.	10.7	287
7	Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition. <i>Nature Communications</i> , 2016, 7, 11589.	12.8	285
8	The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL. <i>Blood</i> , 2018, 132, 2446-2455.	1.4	261
9	Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. <i>Lancet</i> , The, 2021, 397, 892-901.	13.7	260
10	Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. <i>Blood</i> , 2016, 128, 195-203.	1.4	259
11	Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 1973-1980.	1.6	257
12	The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism. <i>Blood</i> , 2016, 127, 3215-3224.	1.4	242
13	Targeting the B-Cell Lymphoma/Leukemia 2 Family in Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 3127-3135.	1.6	236
14	The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. <i>Cancer Cell</i> , 2016, 29, 574-586.	16.8	227
15	Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies. <i>Cancer Cell</i> , 2019, 36, 369-384.e13.	16.8	224
16	Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax. <i>Cancer Discovery</i> , 2017, 7, 156-164.	9.4	164
17	Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables. <i>Blood</i> , 2019, 134, 111-122.	1.4	145
18	Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinase. <i>Future Oncology</i> , 2014, 10, 957-967.	2.4	136

#	ARTICLE	IF	CITATIONS
19	Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia. <i>Clinical Cancer Research</i> , 2018, 24, 4371-4379.	7.0	127
20	Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy. <i>Blood</i> , 2018, 131, 1704-1711.	1.4	122
21	Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia. <i>Blood</i> , 2012, 120, 3501-3509.	1.4	117
22	The rise of apoptosis: targeting apoptosis in hematologic malignancies. <i>Blood</i> , 2018, 132, 1248-1264.	1.4	107
23	Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1b study. <i>Lancet Haematology</i> , 2019, 6, e38-e47.	4.6	98
24	Ibrutinib inhibits CD20 upregulation on CLL B cells mediated by the CXCR4/SDF-1 axis. <i>Blood</i> , 2016, 128, 1609-1613.	1.4	85
25	ABT-199: Taking Dead Aim at BCL-2. <i>Cancer Cell</i> , 2013, 23, 139-141.	16.8	83
26	Association of Advanced Leukemic Stage and Skin Cancer Tumor Stage With Poor Skin Cancer Outcomes in Patients With Chronic Lymphocytic Leukemia. <i>JAMA Dermatology</i> , 2014, 150, 280.	4.1	83
27	Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia. <i>Blood</i> , 2019, 134, 1132-1143.	1.4	81
28	BCL-2 Antagonism to Target the Intrinsic Mitochondrial Pathway of Apoptosis. <i>Clinical Cancer Research</i> , 2015, 21, 5021-5029.	7.0	76
29	Targeting the B cell receptor pathway in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2012, 53, 2362-2370.	1.3	71
30	The BCL-2 antagonist ABT-199 triggers apoptosis, and augments ibrutinib and idelalisib mediated cytotoxicity in CXCR4 ^{hi} and CXCR4 ^{lo} WHIM mutated Waldenstrom macroglobulinaemia cells. <i>British Journal of Haematology</i> , 2015, 170, 134-138.	2.5	63
31	A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation. <i>Blood</i> , 2020, 135, 2182-2191.	1.4	62
32	Statins enhance efficacy of venetoclax in blood cancers. <i>Science Translational Medicine</i> , 2018, 10, .	12.4	61
33	Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial. <i>Lancet Haematology</i> , 2019, 6, e419-e428.	4.6	60
34	Targeting BCL-2 in B-cell lymphomas. <i>Blood</i> , 2017, 130, 1081-1088.	1.4	58
35	Cell Trafficking in Chronic Lymphocytic Leukemia. <i>Open Journal of Hematology</i> , 2012, 3, 1.	0.4	56
36	Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents. <i>Blood Advances</i> , 2020, 4, 3977-3989.	5.2	55

#	ARTICLE	IF	CITATIONS
37	Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study. <i>Lancet Oncology</i> , The, 2021, 22, 1391-1402.	10.7	53
38	Venetoclax in Previously Treated Waldenström Macroglobulinemia. <i>Journal of Clinical Oncology</i> , 2022, 40, 63-71.	1.6	53
39	A phase 2 study of Rituximab+Bendamustine and Rituximab+Cytarabine for transplant-eligible patients with mantle cell lymphoma. <i>British Journal of Haematology</i> , 2016, 173, 89-95.	2.5	51
40	Venetoclax (VEN) Monotherapy for Patients with Chronic Lymphocytic Leukemia (CLL) Who Relapsed after or Were Refractory to Ibrutinib or Idelalisib. <i>Blood</i> , 2016, 128, 637-637.	1.4	48
41	<i>IGHV</i> mutational status testing in chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2017, 92, 1393-1397.	4.1	47
42	The Development and Current Use of BCL-2 Inhibitors for the Treatment of Chronic Lymphocytic Leukemia. <i>Current Hematologic Malignancy Reports</i> , 2017, 12, 11-19.	2.3	44
43	Risk of hepatitis B virus reactivation in patients treated with ibrutinib. <i>Blood</i> , 2018, 131, 1987-1989.	1.4	42
44	Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma. <i>Blood Advances</i> , 2020, 4, 858-867.	5.2	40
45	Immune-related fulminant myocarditis in a patient receiving ipilimumab therapy for relapsed chronic myelomonocytic leukaemia. <i>European Journal of Heart Failure</i> , 2017, 19, 682-685.	7.1	39
46	Splicing modulation sensitizes chronic lymphocytic leukemia cells to venetoclax by remodeling mitochondrial apoptotic dependencies. <i>JCI Insight</i> , 2018, 3, .	5.0	39
47	The molecular pathogenesis of myelodysplastic syndromes. <i>Cancer Biology and Therapy</i> , 2010, 10, 309-319.	3.4	38
48	Long-term Follow-up of Patients with Relapsed or Refractory Non-Hodgkin Lymphoma Treated with Venetoclax in a Phase I, First-in-Human Study. <i>Clinical Cancer Research</i> , 2021, 27, 4690-4695.	7.0	38
49	<i>miR-29</i> modulates CD40 signaling in chronic lymphocytic leukemia by targeting TRAF4: an axis affected by BCR inhibitors. <i>Blood</i> , 2021, 137, 2481-2494.	1.4	37
50	The redox-senescence axis and its therapeutic targeting. <i>Redox Biology</i> , 2021, 45, 102032.	9.0	34
51	The Single-Agent Bcl-2 Inhibitor ABT-199 (GDC-0199) In Patients With Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL): Responses Observed In All Mantle Cell Lymphoma (MCL) Patients. <i>Blood</i> , 2013, 122, 1789-1789.	1.4	32
52	Determination of Recommended Phase 2 Dose of ABT-199 (GDC-0199) Combined with Rituximab (R) in Patients with Relapsed / Refractory (R/R) Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2014, 124, 325-325.	1.4	32
53	Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study. <i>Clinical Cancer Research</i> , 2020, 26, 2096-2103.	7.0	31
54	Longitudinal Single-Cell Dynamics of Chromatin Accessibility and Mitochondrial Mutations in Chronic Lymphocytic Leukemia Mirror Disease History. <i>Cancer Discovery</i> , 2021, 11, 3048-3063.	9.4	31

#	ARTICLE	IF	CITATIONS
55	Venetoclax plus dose-adjusted R-EPOCH for Richter syndrome. <i>Blood</i> , 2022, 139, 686-689.	1.4	29
56	<i>Pneumocystis jirovecii</i> pneumonia and institutional prophylaxis practices in CLL patients treated with BTK inhibitors. <i>Blood Advances</i> , 2020, 4, 1458-1463.	5.2	28
57	Preliminary Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2019, 134, 32-32.	1.4	28
58	Serine-70 phosphorylated Bcl-2 prevents oxidative stress-induced DNA damage by modulating the mitochondrial redox metabolism. <i>Nucleic Acids Research</i> , 2020, 48, 12727-12745.	14.5	27
59	Tyrosine kinase inhibitors and immune checkpoint blockade in allogeneic hematopoietic cell transplantation. <i>Blood</i> , 2018, 131, 1073-1080.	1.4	26
60	BCL-2 Inhibitors, Present and Future. <i>Cancer Journal (Sudbury, Mass)</i> , 2019, 25, 401-409.	2.0	25
61	A phase 1b/2 study of duvelisib in combination with FCR (DFCR) for frontline therapy for younger CLL patients. <i>Leukemia</i> , 2021, 35, 1064-1072.	7.2	25
62	Selective Bcl-2 inhibition to treat chronic lymphocytic leukemia and non-Hodgkin lymphoma. <i>Clinical Advances in Hematology and Oncology</i> , 2014, 12, 224-9.	0.3	25
63	Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation. <i>Blood</i> , 2021, 137, 3212-3217.	1.4	24
64	Overcoming stroma-mediated treatment resistance in chronic lymphocytic leukemia through BCL-2 inhibition. <i>Leukemia and Lymphoma</i> , 2013, 54, 1823-1825.	1.3	23
65	Ongoing Results of a Phase 1B/2 Dose-Escalation and Cohort-Expansion Study of the Selective, Noncovalent, Reversible Bruton'S Tyrosine Kinase Inhibitor, Vencabrutinib, in B-Cell Malignancies. <i>Blood</i> , 2019, 134, 3041-3041.	1.4	23
66	BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia. <i>Blood</i> , 2021, 137, 3495-3506.	1.4	22
67	Multicenter Prospective Phase II Study of Venetoclax in Patients with Previously Treated Waldenstrom Macroglobulinemia. <i>Blood</i> , 2018, 132, 2888-2888.	1.4	22
68	Controversial fluorescence <i>in situ</i> hybridization cytogenetic abnormalities in chronic lymphocytic leukaemia: new insights from a large cohort. <i>British Journal of Haematology</i> , 2015, 170, 694-703.	2.5	19
69	Phase 1b dose-escalation study of the selective, non-covalent, reversible Bruton's tyrosine kinase inhibitor venetoclax in B-cell malignancies. <i>Haematologica</i> , 2022, 107, 984-987.	3.5	19
70	How should we sequence and combine novel therapies in CLL?. <i>Hematology American Society of Hematology Education Program</i> , 2017, 2017, 346-353.	2.5	18
71	Cutaneous eruptions from ibrutinib resembling epidermal growth factor receptor inhibitor-induced dermatologic adverse events. <i>Journal of the American Academy of Dermatology</i> , 2023, 88, 1271-1281.	1.2	18
72	The BCL-2-Specific BH3-Mimetic ABT-199 (GDC-0199) Is Active and Well-Tolerated in Patients with Relapsed Non-Hodgkin Lymphoma: Interim Results of a Phase I Study. <i>Blood</i> , 2012, 120, 304-304.	1.4	18

#	ARTICLE	IF	CITATIONS
73	Targeting constitutively active <sc>STAT3</sc> in chronic lymphocytic leukemia: A clinical trial of the <sc>STAT3</sc> inhibitor pyrimethamine with pharmacodynamic analyses. American Journal of Hematology, 2021, 96, E95-E98.	4.1	17
74	LOXO-305, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Results from the Phase 1/2 BRUIN Study. Blood, 2020, 136, 35-37.	1.4	16
75	Updated Safety and Efficacy Results from a Phase 2 Study of Acabrutinib, Venetoclax and Obinutuzumab (AVO) for Frontline Treatment of Chronic Lymphocytic Leukemia (CLL). Blood, 2020, 136, 20-21.	1.4	16
76	Increased mitochondrial apoptotic priming of human regulatory T cells after allogeneic hematopoietic stem cell transplantation. Haematologica, 2014, 99, 1499-1508.	3.5	15
77	Comparative Efficacy of Acabrutinib in Frontline Treatment of Chronic Lymphocytic Leukemia: A Systematic Review and Network Meta-analysis. Clinical Therapeutics, 2020, 42, 1955-1974.e15.	2.5	15
78	Allogeneic hematopoietic cell transplantation outcomes in patients with Richter's transformation. Haematologica, 2021, 106, 3219-3222.	3.5	15
79	Ibrutinib Therapy Increases BCL-2 Dependence and Enhances Sensitivity to Venetoclax in CLL. Blood, 2015, 126, 490-490.	1.4	15
80	Initial Results of a Multicenter, Phase II Study of Ibrutinib Plus FCR (iFCR) As Frontline Therapy for Younger CLL Patients. Blood, 2016, 128, 3243-3243.	1.4	15
81	FISHing in the dark: How the combination of FISH and conventional karyotyping improves the diagnostic yield in CpG-stimulated chronic lymphocytic leukemia. American Journal of Hematology, 2016, 91, 978-983.	4.1	14
82	Isavuconazole for the treatment of invasive fungal disease in patients receiving ibrutinib. Leukemia and Lymphoma, 2019, 60, 527-530.	1.3	14
83	IL4-STAT6 signaling induces CD20 in chronic lymphocytic leukemia and this axis is repressed by PI3K inhibitor idelalisib. Haematologica, 2021, 106, 2995-2999.	3.5	14
84	A T cell inflammatory phenotype is associated with autoimmune toxicity of the PI3K inhibitor duvelisib in chronic lymphocytic leukemia. Leukemia, 2021, , .	7.2	14
85	Integrated safety analysis of umbralisib, a dual PI3K/CK1 inhibitor, in relapsed/refractory lymphoid malignancies. Blood Advances, 2021, 5, 5332-5343.	5.2	13
86	Updated Results from a Phase I/II Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory CLL/SLL or Richter's Syndrome. Blood, 2020, 136, 46-47.	1.4	13
87	Pooled Multi-Trial Analysis of Venetoclax Efficacy in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia. Blood, 2016, 128, 3230-3230.	1.4	12
88	Budget Impact of 12-Month Fixed Treatment Duration Venetoclax in Combination with Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia Patients in the United States. Pharmacoeconomics, 2020, 38, 941-951.	3.3	11
89	Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report. Clinical Cancer Research, 2019, 25, 5143-5155.	7.0	10
90	Psoriasiform eruptions secondary to phosphoinositide 3-kinase inhibition. JAAD Case Reports, 2019, 5, 401-405.	0.8	10

#	ARTICLE	IF	CITATIONS
91	A Phase I/Ib Study of Nivolumab for Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation (alloHCT). <i>Blood</i> , 2018, 132, 705-705.	1.4	10
92	TGR-1202 in Combination with Ibrutinib in Patients with Relapsed or Refractory CLL or MCL: Preliminary Results of a Multicenter Phase I/Ib Study. <i>Blood</i> , 2016, 128, 641-641.	1.4	10
93	Assessing Surge Capacity for Radiation Victims with Marrow Toxicity. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 1436-1441.	2.0	9
94	Safety and Efficacy of Decitabine Plus Ipilimumab in Relapsed or Refractory MDS/AML in the Post-BMT or Transplant Na ⁺ ve Settings. <i>Blood</i> , 2020, 136, 15-17.	1.4	9
95	Phosphoinositide 3 ⁺ -Kinase Inhibition in Chronic Lymphocytic Leukemia. <i>Hematology/Oncology Clinics of North America</i> , 2013, 27, 329-339.	2.2	8
96	Matching-adjusted indirect comparisons of safety and efficacy of acalabrutinib versus other targeted therapies in patients with treatment-na ⁺ ve chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 2342-2351.	1.3	8
97	Cost-Effectiveness of a 12-Month Fixed Duration of Venetoclax in Combination with Obinutuzumab in First-Line Chronic Lymphocytic Leukemia in the United States. <i>Blood</i> , 2019, 134, 4741-4741.	1.4	8
98	Update On The Safety and Efficacy Of The Pan Class I PI3K Inhibitor SAR245408 (XL147) In Chronic Lymphocytic Leukemia and Non-Hodgkin ⁺ 's Lymphoma Patients. <i>Blood</i> , 2013, 122, 4170-4170.	1.4	8
99	Cost-effectiveness of a 12-month fixed-duration venetoclax treatment in combination with obinutuzumab in first-line, unfit chronic lymphocytic leukemia in the United States. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2021, 27, 1532-1544.	0.9	8
100	Identification of recurrent genomic alterations in the apoptotic machinery in chronic lymphocytic leukemia patients treated with venetoclax monotherapy. <i>American Journal of Hematology</i> , 2022, 97, .	4.1	8
101	Pirtobrutinib, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Updated Results from the Phase 1/2 BRUIN Study. <i>Blood</i> , 2021, 138, 391-391.	1.4	8
102	Venetoclax for the treatment of patients with chronic lymphocytic leukemia. <i>Future Oncology</i> , 2017, 13, 1223-1232.	2.4	7
103	Rationale for the combination of venetoclax and ibrutinib in T-prolymphocytic leukemia. <i>Haematologica</i> , 2021, 106, 2251-2256.	3.5	7
104	The Fully Human Anti-CD47 Antibody SRF231 Has Dual-Mechanism Antitumor Activity Against Chronic Lymphocytic Leukemia (CLL) Cells and Increases the Activity of Both Rituximab and Venetoclax. <i>Blood</i> , 2018, 132, 4393-4393.	1.4	7
105	Outcomes of Ibrutinib (Ibr) Therapy in Ibr-Na ⁺ ve Patients (pts) with Chronic Lymphocytic Leukemia (CLL) Progressing after Venetoclax (Ven). <i>Blood</i> , 2019, 134, 4320-4320.	1.4	7
106	Safety Profile of Venetoclax Monotherapy in Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , 2016, 128, 4395-4395.	1.4	7
107	Immune Reconstitution following High-Dose Chemotherapy and Autologous Stem Cell Transplantation with or without Pembrolizumab Maintenance Therapy in Patients with Lymphoma. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 32.e1-32.e10.	1.2	7
108	MEDICAL MANAGEMENT OF RADIATION VICTIMS IN THE UNITED STATES. <i>Health Physics</i> , 2010, 98, 833-837.	0.5	6

#	ARTICLE	IF	CITATIONS
109	Boldly Targeting Kinases without mutations. <i>Blood</i> , 2014, 123, 1119-1121.	1.4	6
110	Breaking through BCL-2 inhibition in CLL. <i>Blood</i> , 2020, 135, 709-711.	1.4	6
111	A Phase I Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory CLL / SLL. <i>Blood</i> , 2019, 134, 1763-1763.	1.4	6
112	Rituximab/Bendamustine and Rituximab/Cytarabine (RB/RC) Induction Chemotherapy for Transplant-Eligible Patients with Mantle Cell Lymphoma: A Pooled Analysis of Two Phase 2 Clinical Trials and Off-Trial Experience. <i>Blood</i> , 2018, 132, 145-145.	1.4	5
113	A complex case of ibrutinib treatment for a <sc>CLL</sc> patient on haemodialysis. <i>British Journal of Haematology</i> , 2018, 181, 854-857.	2.5	4
114	Genetic Determinants of Venetoclax Resistance in Lymphoid Malignancies. <i>Blood</i> , 2018, 132, 893-893.	1.4	4
115	Early Adoption and Outcomes of Ibrutinib As Treatment for Older Patients with Chronic Lymphocytic Leukemia (CLL): A Population-Based Study. <i>Blood</i> , 2019, 134, 265-265.	1.4	4
116	A Multicenter, Retrospective Study of Accelerated Venetoclax Ramp-up in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia. <i>Blood</i> , 2020, 136, 51-52.	1.4	4
117	A deep molecular response of splenic marginal zone lymphoma to front-line checkpoint blockade. <i>Haematologica</i> , 2021, 106, 651-654.	3.5	4
118	ReVenG: A Phase 2 Study of Venetoclax Plus Obinutuzumab Retreatment in Patients with Relapsed Chronic Lymphocytic Leukemia. <i>Blood</i> , 2021, 138, 2634-2634.	1.4	4
119	Longer Term Follow-up of a Multicenter, Phase 2 Study of Ibrutinib Plus Fludarabine, Cyclophosphamide, Rituximab (iFCR) As Initial Therapy for Younger Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , 2021, 138, 640-640.	1.4	4
120	BRUIN CLL-322: A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib Plus Venetoclax and Rituximab Versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Trial in Progress). <i>Blood</i> , 2021, 138, 3742-3742.	1.4	4
121	Prognostic Value of Circulating Tumor DNA (ctDNA) in Autologous Stem Cell Graft and Post-Transplant Plasma Samples Among Patients with Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2020, 136, 22-23.	1.4	4
122	Synchronous squamous cell carcinoma and diffuse large B-cell lymphoma of the head and neck: the odd couple. <i>BJR</i> case Reports, 2016, 2, 20150271.	0.2	3
123	Review of targeted therapy in chronic lymphocytic leukemia: what a radiologist needs to know about CT interpretation. <i>Cancer Imaging</i> , 2018, 18, 13.	2.8	3
124	Ofatumumab plus high dose methylprednisolone followed by ofatumumab plus alemtuzumab to achieve maximal cytoreduction prior to allogeneic transplantation for 17p deleted or TP53 mutated chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2019, 60, 1312-1315.	1.3	3
125	Systematic literature review of the global burden of illness of mantle cell lymphoma. <i>Current Medical Research and Opinion</i> , 2020, 36, 843-852.	1.9	3
126	Addition of rituximab in relapsed/refractory chronic lymphocytic leukemia after progression on venetoclax monotherapy. <i>EJHaem</i> , 2021, 2, 266-271.	1.0	3

#	ARTICLE	IF	CITATIONS
127	Phase I Trial of SAR245408 (S08), a Pan-Phosphatidylinositol 3 Kinase (PI3K) Inhibitor, in Patients with Chronic Lymphocytic Leukemia (CLL) and Lymphoma. <i>Blood</i> , 2011, 118, 2683-2683.	1.4	3
128	The BCL-2-Specific BH3-Mimetic ABT-199 (GDC-0199) Is Active and Well-Tolerated in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Interim Results of a Phase I First-in-Human Study. <i>Blood</i> , 2012, 120, 3923-3923.	1.4	3
129	Clinical and Immunologic Activity of Ipilimumab Following Decitabine Priming in Post-Allogeneic Transplant and Transplant-Naïve Patients with Relapsed or Refractory Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Multi-Center Phase 1, Two-Arm, Dose-Escalation Study. <i>Blood</i> , 2019, 134, 2015-2015.	1.4	3
130	A Phase I Trial of PI3K Inhibitor Copanlisib in Combination with Nivolumab in Patients with Richter's Transformation (RT) or Transformed Non-Hodgkin Lymphoma (tNHL). <i>Blood</i> , 2021, 138, 3558-3558.	1.4	3
131	Preliminary Study of Ruxolitinib and Venetoclax for Treatment of Patients with T-Cell Prolymphocytic Leukemia Refractory to, or Ineligible for Alemtuzumab. <i>Blood</i> , 2021, 138, 1201-1201.	1.4	3
132	Genetic Determinants and Evolutionary History of Richter's Syndrome. <i>Blood</i> , 2020, 136, 47-48.	1.4	3
133	A multicenter, retrospective study of accelerated venetoclax ramp-up in patients with relapsed/refractory chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2022, 97, .	4.1	3
134	Is Bcl-2 a valid target in the treatment of indolent non-Hodgkin lymphoma?. <i>Leukemia and Lymphoma</i> , 2014, 55, 2675-2677.	1.3	2
135	The Evolving Role of Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia. <i>Current Hematologic Malignancy Reports</i> , 2015, 10, 18-27.	2.3	2
136	Longitudinal health-related quality of life in first-line treated patients with chronic lymphocytic leukemia: Results from the Connect CLL Registry. <i>EJHaem</i> , 2020, 1, 188-198.	1.0	2
137	Clinical and Biological Indicators of Duvelisib Efficacy in CLL from the Phase 3 DUOTM Study. <i>Blood</i> , 2018, 132, 1856-1856.	1.4	2
138	The Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL: Updated Results from the DUO Crossover Extension Study. <i>Blood</i> , 2018, 132, 3140-3140.	1.4	2
139	Characterizing the Anti-Apoptotic Dependencies of T-Cell Prolymphocytic Leukemia Identifies HDAC and JAK/STAT Pathway Inhibitors As Promising Combination Partners to Augment Bcl-2 Targeted Killing By Venetoclax. <i>Blood</i> , 2019, 134, 807-807.	1.4	2
140	Acalabrutinib Increases Mitochondrial Priming and Enhances Venetoclax Sensitivity in CLL Cells. <i>Blood</i> , 2016, 128, 4346-4346.	1.4	2
141	BH3 Profiling Demonstrates That Restoration of Apoptotic Priming Contributes to Increased Sensitivity to PI3K Inhibition in Stroma-Exposed Chronic Lymphocytic Leukemia Cells. <i>Blood</i> , 2011, 118, 974-974.	1.4	2
142	Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocyteic Leukemia Patients Who Underwent Reduced Intensity Conditioning Allogeneic HCT: A CIBMTR Report. <i>Blood</i> , 2017, 130, 667-667.	1.4	2
143	Majic: A Phase 3 Prospective, Multicenter, Randomized, Open-Label Trial of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma. <i>Blood</i> , 2021, 138, 1553-1553.	1.4	2
144	Worldwide Examination of Patients with CLL Hospitalized for COVID-19. <i>Blood</i> , 2020, 136, 45-49.	1.4	2

#	ARTICLE	IF	CITATIONS
145	Safety profiles of novel agent therapies in CLL. Hematology American Society of Hematology Education Program, 2017, 2017, 354-357.	2.5	1
146	Acalabrutinib for the initial treatment of chronic lymphocytic leukaemia. Lancet, The, 2020, 395, 1234-1236.	13.7	1
147	Characterization of the Long-Term Efficacy and Safety of Duvelisib Monotherapy in Patients with Relapsed/Refractory CLL/SLL on Treatment for > 2 Years across 4 Clinical Studies. Blood, 2018, 132, 3146-3146.	1.4	1
148	High Sensitivity NGS Analysis of MRD in CLL Patients Prospectively Treated with Ibrutinib Plus FCR (iFCR). Blood, 2019, 134, 4291-4291.	1.4	1
149	Combination of Venetoclax and Ibrutinib Increases bcl2-Dependent Apoptotic Priming, Reduces ITK-Phosphorylation and Is Clinically Promising in Relapsed/Refractory T-Prolymphocytic Leukemia. Blood, 2019, 134, 3965-3965.	1.4	1
150	Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Is Highly BCL-2 Dependent and Sensitive to Venetoclax. Blood, 2016, 128, 4045-4045.	1.4	1
151	An Innovative Telemedicine Platform to Provide Expert Access to Patients with Chronic Lymphocytic Leukemia (CLL). Blood, 2019, 134, 4716-4716.	1.4	1
152	Matching-Adjusted Indirect Treatment Comparison (MAIC) of Acalabrutinib Alone or in Combination with Obinutuzumab Versus Ibrutinib or Venetoclax Plus Obinutuzumab in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia. Blood, 2021, 138, 2633-2633.	1.4	1
153	Local and Systemic Effects of Immune Checkpoint Blockade on Relapsed Myeloid Malignancies Following Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2020, 136, 34-35.	1.4	1
154	Interim Positron Emission Tomography (iPET) Assessed Using Deauville Score for Patients with Follicular Lymphoma Receiving First-Line Chemoimmunotherapy. Blood, 2020, 136, 37-38.	1.4	1
155	A new triple threat to CLL. Blood, 2018, 132, 1547-1548.	1.4	0
156	Idelalisib in indolent NHL “ has it finally found its niche?. Leukemia and Lymphoma, 2021, 62, 1029-1030.	1.3	0
157	Twists and turns from “tumor in tumor” profiling: surveillance of chronic lymphocytic leukemia (CLL) leads to detection of a lung adenocarcinoma, whose genomic characterization alters the original hematologic diagnosis. Journal of Physical Education and Sports Management, 2021, 7, a006089.	1.2	0
158	BH3 Profiling Demonstrates Decreased Mitochondrial Priming for Apoptosis In Primary CLL Cells Exposed to Stroma. Blood, 2010, 116, 692-692.	1.4	0
159	Rearrangement of 14q32 in the Absence of t(14;18) Is Associated with Short Time to First Treatment in Chronic Lymphocytic Leukemia. Blood, 2011, 118, 1438-1438.	1.4	0
160	Prior Treatment with Chemotherapy Is Associated with Poor Outcomes of High Risk Skin Cancers in Patients with Chronic Lymphocytic Leukemia. Blood, 2012, 120, 3920-3920.	1.4	0
161	Prognostic Factors for Patients with Diffuse Large B Cell Lymphoma and Transformed Indolent Lymphoma Undergoing Autologous Stem Cell Transplantation in the PET Era. Blood, 2012, 120, 1980-1980.	1.4	0
162	Therapeutic Targeting of the Bcl2 Family. Blood, 2013, 122, SCI-42-SCI-42.	1.4	0

#	ARTICLE	IF	CITATIONS
163	Chronic Lymphocytic Leukemia (CLL) Transformed into Hodgkin Lymphoma (HL): Clinical Characteristics and Outcomes from a Large Multi-Center Collaboration. <i>Blood</i> , 2018, 132, 1648-1648.	1.4	0
164	Systematic Reviews of the Clinical Efficacy and Safety of First-Line Treatments for Patients with Mantle Cell Lymphoma. <i>Blood</i> , 2018, 132, 5868-5868.	1.4	0
165	Systematic Literature Review of the Cost-Effectiveness of Treatments, Costs/Resource Use, and Quality of Life in Patients with Mantle Cell Lymphoma. <i>Blood</i> , 2018, 132, 5848-5848.	1.4	0
166	Characterizing Specificities of Chronic Lymphoid Leukemia Harboring a BCL2 rearrangement. <i>Blood</i> , 2020, 136, 29-30.	1.4	0
167	Improving Physician-Patient Decision Making for Treatment of Chronic Lymphocytic Leukemia with BTK Inhibition. <i>Blood</i> , 2020, 136, 20-20.	1.4	0
168	CCR2 Expression Signature Can Classify and Predict Outcome in a Subpopulation of Chronic Lymphocytic Leukemia (CLL) Patients. <i>Blood</i> , 2020, 136, 13-14.	1.4	0
169	Highlights in chronic lymphocytic leukemia from the 62nd American Society of Hematology Annual Meeting and Exposition: commentary. <i>Clinical Advances in Hematology and Oncology</i> , 2021, 19 Suppl 4, 21-23.	0.3	0